TY - JOUR
T1 - 3D Tumor-Mimicking Phantom Models for Assessing NIR I/II Nanoparticles in Fluorescence-Guided Surgical Interventions
AU - Harun, Asma
AU - Bendele, Nathaniel
AU - Khalil, Mohammad Ibrahim
AU - Vasquez, Isabella
AU - Djuanda, Jonathan
AU - Posey, Robert
AU - Rashid, Md Hasnat
AU - Christopher, Gordon F.
AU - Bickel, Ulrich
AU - Gruev, Viktor
AU - Tropp, Joshua
AU - Egan, Paul F.
AU - Srivastava, Indrajit
N1 - I.S. acknowledges the Edward E. Whitacre Jr. College of Engineering and Texas Tech University for research support. I.S. acknowledges partial support from American Heart Association ( 10.58275/AHA.25AIREA1372884.pc.gr.226920 ). Imaging studies on the IR VIVO system was funded by the Core Facility Support Award (grant number RP200572) from the Cancer Prevention and Research Institute of Texas (CPRIT) to the Imaging Core, Texas Tech University Health Sciences Center at Amarillo. The authors acknowledge Dr. Benjamin Lew and Jamie Ludwig for assistance in in vivo imaging studies. All graphics in this paper were made in Biorender.
PY - 2025/5/16
Y1 - 2025/5/16
N2 - Fluorescence image-guided surgery (FIGS) offers high spatial resolution and real-time feedback but is limited by shallow tissue penetration and autofluorescence from current clinically approved fluorophores. The near-infrared (NIR) spectrum, specifically the NIR-I (700-900 nm) and NIR-II (950-1700 nm), addresses these limitations with deeper tissue penetration and improved signal-to-noise ratios. However, biological barriers and suboptimal optical performance under surgical conditions have hindered the clinical translation of NIR-I/II nanoprobes. In vivo mouse models have shown promise, but these models do not replicate the complex optical scenarios encountered during real-world surgeries. Existing tissue-mimicking phantoms used to evaluate NIR-I/II imaging systems are useful but fall short when assessing nanoprobes in surgical environments. These phantoms often fail to replicate the tumor microenvironment, limiting their predictive assessment. To overcome these challenges, we propose developing tumor-mimicking phantom models (TMPs) that integrate key tumor features, such as tunable tumor cell densities, in vivo-like nanoparticle concentrations, biologically relevant factors (pH, enzymes), replicate light absorption components (hemoglobin), and light scattering components (intralipid). These TMPs enable more clinically relevant assessments of NIR-I/II nanoprobes, including optical tissue penetration profiling, tumor margin delineation, and ex vivo thoracic surgery on porcine lungs. The components of TMPs can be further modulated to closely match the optical profiles of in vivo and ex vivo tumors. Additionally, 3D bioprinting technology facilitates a high-throughput platform for screening nanoprobes under realistic conditions. This approach will identify high-performing NIR-I/II probes with superior surgical utility, bridging the gap between preclinical findings and clinical applications, and ensuring results extend beyond traditional in vivo mouse studies.
AB - Fluorescence image-guided surgery (FIGS) offers high spatial resolution and real-time feedback but is limited by shallow tissue penetration and autofluorescence from current clinically approved fluorophores. The near-infrared (NIR) spectrum, specifically the NIR-I (700-900 nm) and NIR-II (950-1700 nm), addresses these limitations with deeper tissue penetration and improved signal-to-noise ratios. However, biological barriers and suboptimal optical performance under surgical conditions have hindered the clinical translation of NIR-I/II nanoprobes. In vivo mouse models have shown promise, but these models do not replicate the complex optical scenarios encountered during real-world surgeries. Existing tissue-mimicking phantoms used to evaluate NIR-I/II imaging systems are useful but fall short when assessing nanoprobes in surgical environments. These phantoms often fail to replicate the tumor microenvironment, limiting their predictive assessment. To overcome these challenges, we propose developing tumor-mimicking phantom models (TMPs) that integrate key tumor features, such as tunable tumor cell densities, in vivo-like nanoparticle concentrations, biologically relevant factors (pH, enzymes), replicate light absorption components (hemoglobin), and light scattering components (intralipid). These TMPs enable more clinically relevant assessments of NIR-I/II nanoprobes, including optical tissue penetration profiling, tumor margin delineation, and ex vivo thoracic surgery on porcine lungs. The components of TMPs can be further modulated to closely match the optical profiles of in vivo and ex vivo tumors. Additionally, 3D bioprinting technology facilitates a high-throughput platform for screening nanoprobes under realistic conditions. This approach will identify high-performing NIR-I/II probes with superior surgical utility, bridging the gap between preclinical findings and clinical applications, and ensuring results extend beyond traditional in vivo mouse studies.
KW - 3D bioprinting
KW - deep tissue imaging
KW - ex vivo tissues
KW - image-guided surgery
KW - phantoms
KW - tumor delineation
UR - http://www.scopus.com/inward/record.url?scp=105005217928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105005217928&partnerID=8YFLogxK
U2 - 10.1021/acsnano.5c01919
DO - 10.1021/acsnano.5c01919
M3 - Article
C2 - 40378397
AN - SCOPUS:105005217928
SN - 1936-0851
VL - 19
SP - 19757
EP - 19776
JO - ACS Nano
JF - ACS Nano
IS - 21
ER -